Mural Oncology in the spotlight (part II)

Assessing IL-18 for cancer treatment

One of the names we wrote about back in mid-December as a trade due to its ample cash position and negative enterprise value was Mural Oncology (MURA). MURA has rallied 50% since then, but now there is also another trend that could act as a tailwind.

MURA was a recent spinout from Alkermes’ (ALKS) oncology division. MURA has $275M in cash and 16.7M share…